[go: up one dir, main page]

NO316733B1 - Prostaglandinagonister og anvendelse derav, samt farmasoytisk preparat og sett - Google Patents

Prostaglandinagonister og anvendelse derav, samt farmasoytisk preparat og sett Download PDF

Info

Publication number
NO316733B1
NO316733B1 NO20001754A NO20001754A NO316733B1 NO 316733 B1 NO316733 B1 NO 316733B1 NO 20001754 A NO20001754 A NO 20001754A NO 20001754 A NO20001754 A NO 20001754A NO 316733 B1 NO316733 B1 NO 316733B1
Authority
NO
Norway
Prior art keywords
phenyl
pharmaceutically acceptable
acceptable salt
acid
methyl
Prior art date
Application number
NO20001754A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001754L (no
NO20001754D0 (no
Inventor
Robert Louis Rosati
Kimberly O'keefe Cameron
Bruce Allen Lefker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20001754D0 publication Critical patent/NO20001754D0/no
Publication of NO20001754L publication Critical patent/NO20001754L/no
Publication of NO316733B1 publication Critical patent/NO316733B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO20001754A 1997-10-10 2000-04-05 Prostaglandinagonister og anvendelse derav, samt farmasoytisk preparat og sett NO316733B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6172797P 1997-10-10 1997-10-10
PCT/IB1998/001540 WO1999019300A1 (en) 1997-10-10 1998-10-05 Prostaglandin agonists and their use to treat bone disorders

Publications (3)

Publication Number Publication Date
NO20001754D0 NO20001754D0 (no) 2000-04-05
NO20001754L NO20001754L (no) 2000-06-07
NO316733B1 true NO316733B1 (no) 2004-04-14

Family

ID=22037728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001754A NO316733B1 (no) 1997-10-10 2000-04-05 Prostaglandinagonister og anvendelse derav, samt farmasoytisk preparat og sett

Country Status (44)

Country Link
US (2) US6498172B1 (es)
EP (1) EP1021410B1 (es)
JP (3) JP3664651B2 (es)
KR (1) KR100369697B1 (es)
CN (2) CN1211367C (es)
AP (1) AP1156A (es)
AR (1) AR015954A1 (es)
AT (1) ATE349428T1 (es)
AU (1) AU731509B2 (es)
BG (1) BG65238B1 (es)
BR (1) BR9813028A (es)
CA (1) CA2305548C (es)
DE (1) DE69836752T2 (es)
DK (1) DK1021410T3 (es)
DZ (1) DZ2621A1 (es)
EA (1) EA003396B1 (es)
ES (1) ES2277390T3 (es)
GT (2) GT199800158A (es)
HN (1) HN1998000157A (es)
HR (1) HRP20000201B1 (es)
HU (1) HUP0100101A3 (es)
ID (1) ID24836A (es)
IL (2) IL134851A0 (es)
IS (1) IS5405A (es)
MA (1) MA26551A1 (es)
MY (1) MY129189A (es)
NO (1) NO316733B1 (es)
NZ (1) NZ503165A (es)
OA (1) OA11346A (es)
PA (1) PA8461301A1 (es)
PE (1) PE121199A1 (es)
PL (1) PL340014A1 (es)
PT (1) PT1021410E (es)
RS (1) RS50012B (es)
SA (2) SA98190804B1 (es)
SI (1) SI1021410T1 (es)
SK (1) SK286136B6 (es)
TN (1) TNSN98182A1 (es)
TR (1) TR200000927T2 (es)
TW (1) TW570913B (es)
UA (1) UA67754C2 (es)
UY (1) UY25204A1 (es)
WO (1) WO1999019300A1 (es)
ZA (1) ZA989230B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) * 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
ES2232434T3 (es) 1999-03-05 2005-06-01 Duke University Analogos de prostaglandinas c-16 fp selectivas insaturadas.
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU2002365969A1 (en) * 2001-11-20 2003-06-10 Scott Bruder Flowable osteogenic and chondrogenic compositions
CN1599598A (zh) * 2001-11-30 2005-03-23 美国辉瑞有限公司 骨生长促进性化合物的控释聚合组合物
PL370914A1 (en) * 2001-11-30 2005-06-13 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
CN1625549A (zh) * 2002-01-31 2005-06-08 辉瑞产品公司 (3－{[4－叔丁基－苄基)－(吡啶－3－磺酰基)－氨基]－甲基}－苯氧基)－乙酸的代谢物
EP1495005A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2486651A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
CA2486644A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Anilino liver x-receptor modulators
JP2006021998A (ja) * 2002-07-18 2006-01-26 Ono Pharmaceut Co Ltd Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
BRPI0408061A (pt) * 2003-03-04 2006-02-14 Pfizer Prod Inc tratamento médico utilizando um agonista de receptores seletivos de ep 2
JP4666257B2 (ja) 2003-07-25 2011-04-06 小野薬品工業株式会社 軟骨関連疾患治療剤
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
JP2008503561A (ja) * 2004-06-21 2008-02-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 骨芽細胞機能を刺激するためのｐｙｋ２阻害薬
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN101237885B (zh) 2005-06-03 2011-01-19 小野药品工业株式会社 神经再生和/或保护剂
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
CN101495452B (zh) * 2006-07-28 2012-04-25 辉瑞产品公司 Ep2激动剂
RS20090002A (sr) 2006-07-28 2010-06-30 Pfizer Products Inc. Agonisti ep2
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
WO2008073748A1 (en) * 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
HUE025137T2 (en) * 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
US20110046385A1 (en) * 2007-08-29 2011-02-24 Pfizer Products Inc. Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
CA2697950A1 (en) * 2007-08-29 2009-03-05 Pfizer Products Inc. Polymorphs of prostaglandin agonists and methods for making the same
WO2009027803A2 (en) * 2007-08-29 2009-03-05 Pfizer Products Inc. Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
DK2264009T3 (en) * 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
JPWO2011078303A1 (ja) 2009-12-25 2013-05-09 宇部興産株式会社 アミノピリジン化合物
EP2617415B1 (en) 2010-09-16 2016-04-20 Catholic Kwandong University Industry Foundation Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
AU2012313971B2 (en) 2011-09-27 2016-09-29 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
US8772541B2 (en) * 2011-12-15 2014-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2014133059A1 (ja) 2013-02-28 2014-09-04 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
HK1220457A1 (zh) 2013-03-28 2017-05-05 宇部兴产株式会社 取代联芳基化合物
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
JP2017206444A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換フェニル化合物
CN114591227A (zh) * 2021-12-28 2022-06-07 上海冬洋生物科技有限公司 一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3442890A (en) 1965-06-15 1969-05-06 Mead Johnson & Co Substituted 3-benzazocin-16-ones
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (es) 1973-06-25 1975-03-01
SE7414770L (es) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) * 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA1214170A (fr) 1981-06-16 1986-11-18 Patrick Choay Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
FI832935A7 (fi) 1982-08-20 1984-02-21 Midit Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en) 1989-07-05 1992-01-14 Kotobuki Seiyaku Co., Ltd. Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) * 1990-07-09 1992-03-03 Nippon Telegr & Teleph Corp <Ntt> 偏波保持光ファイバ
GB9110722D0 (en) * 1991-05-17 1991-07-10 Fujisawa Pharmaceutical Co Amine derivatives
GB9116732D0 (en) * 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
CA2113787A1 (en) 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. New use
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
PL370914A1 (en) * 2001-11-30 2005-06-13 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
CN1625549A (zh) * 2002-01-31 2005-06-08 辉瑞产品公司 (3－{[4－叔丁基－苄基)－(吡啶－3－磺酰基)－氨基]－甲基}－苯氧基)－乙酸的代谢物

Also Published As

Publication number Publication date
NO20001754L (no) 2000-06-07
AP9801356A0 (en) 1998-12-31
NO20001754D0 (no) 2000-04-05
ATE349428T1 (de) 2007-01-15
SI1021410T1 (sl) 2007-06-30
AU9181598A (en) 1999-05-03
SA98190804A (ar) 2005-12-03
WO1999019300A1 (en) 1999-04-22
ES2277390T3 (es) 2007-07-01
UY25204A1 (es) 2000-12-29
KR20010031035A (ko) 2001-04-16
SA06260449B1 (ar) 2007-08-07
EP1021410B1 (en) 2006-12-27
AP1156A (en) 2003-06-30
HK1031884A1 (en) 2001-06-29
ID24836A (id) 2000-08-24
HRP20000201B1 (en) 2003-06-30
TR200000927T2 (tr) 2000-11-21
HRP20000201A2 (en) 2000-06-30
US20030078261A1 (en) 2003-04-24
SK286136B6 (sk) 2008-04-07
AU731509B2 (en) 2001-03-29
BG65238B1 (bg) 2007-09-28
JP2004155759A (ja) 2004-06-03
PT1021410E (pt) 2007-02-28
BG104315A (en) 2000-12-29
IL134851A (en) 2007-06-17
SK4752000A3 (en) 2001-05-10
TW570913B (en) 2004-01-11
JP2007246532A (ja) 2007-09-27
KR100369697B1 (ko) 2003-02-05
CA2305548C (en) 2008-12-02
PA8461301A1 (es) 2000-05-24
DE69836752D1 (de) 2007-02-08
DK1021410T3 (da) 2007-04-02
JP4031736B2 (ja) 2008-01-09
CN1275123A (zh) 2000-11-29
OA11346A (en) 2003-12-11
CN1211367C (zh) 2005-07-20
EA003396B1 (ru) 2003-04-24
US7442702B2 (en) 2008-10-28
EA200000298A1 (ru) 2000-10-30
PE121199A1 (es) 1999-12-02
YU18400A (sh) 2003-08-29
US6498172B1 (en) 2002-12-24
IL134851A0 (en) 2001-05-20
GT199800158AA (es) 2000-04-01
SA98190804B1 (ar) 2006-07-30
CN1566096A (zh) 2005-01-19
MY129189A (en) 2007-03-30
BR9813028A (pt) 2000-08-15
JP4796006B2 (ja) 2011-10-19
JP3664651B2 (ja) 2005-06-29
TNSN98182A1 (fr) 2005-03-15
HUP0100101A3 (en) 2001-12-28
NZ503165A (en) 2001-07-27
AR015954A1 (es) 2001-05-30
HUP0100101A2 (hu) 2001-06-28
ZA989230B (en) 2000-04-10
RS50012B (sr) 2008-09-29
DE69836752T2 (de) 2007-10-11
EP1021410A1 (en) 2000-07-26
PL340014A1 (en) 2001-01-15
IS5405A (is) 2000-03-14
UA67754C2 (uk) 2004-07-15
CA2305548A1 (en) 1999-04-22
MA26551A1 (fr) 2004-12-20
DZ2621A1 (fr) 2003-03-08
HN1998000157A (es) 1999-06-02
GT199800158A (es) 2000-04-01
JP2001519414A (ja) 2001-10-23

Similar Documents

Publication Publication Date Title
NO316733B1 (no) Prostaglandinagonister og anvendelse derav, samt farmasoytisk preparat og sett
US6649657B2 (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
MXPA05009398A (es) Uso de agonistas selectivos del receptor ep2 en tratamiento medico.
CA2697950A1 (en) Polymorphs of prostaglandin agonists and methods for making the same
MXPA00003478A (es) Agonistas de prostaglandinas
CZ20001280A3 (cs) Agonisté prostaglandinu a jejich použití pro léčení chorob kostí
HK1031884B (en) Prostaglandin agonists and their use to treat bone disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees